Fig. 3
From: Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin
12% SDS-PAGE of the recombinant immunotoxins showing their expression, solubility and refolding yield. a Cell lysate was extracted after the expression of recombinant HALT-1-scFv in BL21(DE3) E. coli cells. Lane 1, 10–250 kDa protein ladder; lane 2, HALT-1-scFv in the presence of IPTG; lane 3, HALT-1-scFv in the absence of IPTG. b Cell lysate was extracted after the expression of recombinant scFv-HALT-1 in BL21(DE3) E. coli cells. Lane 1, 10–250 kDa protein ladder; lane 2, scFv-HALT-1 in the presence of IPTG; lane 3, scFv-HALT-1 in the absence of IPTG. c Solubility of HALT-1-scFv was examined after the cell disruption by sonication. Lane 1, 10–250 kDa protein ladder; lane 2, HALT-1-scFv insoluble faction; lane 3, HALT-1-scFv soluble fraction. d Solubility of scFv-HALT-1 was examined after the cell disruption by sonication. Lane 1, 10–250 kDa protein ladder; lane 2, scFv-HALT-1 insoluble faction; lane 3, scFv-HALT-1 soluble fraction. e Recombinant HALT-1-scFv after the refolding process. Lane 1, 12–120 kDa protein ladder; lane 2, HALT-1-scFv. f Recombinant scFv-HALT-1 after the refolding process. Lane 1, 12–120 kDa protein ladder; lane 2, scFv-HALT-1. See also Figure S2; Additional file 2